Renaissance Capital logo

EVLO News

US IPO Weekly Recap: AXA is year's largest IPO, but Chinese tech steals the show

EQH

This week featured the largest IPO of 2018, AXA Equitable. Yet, another spin-off stole the show, as fast-growing Chinese tech company HUYA popped 34%. Thanks to AXA and several billion-dollar IPOs in the 1Q18, the US IPO market has raised...read more

A gut feeling: Evelo Biosciences prices IPO at $16 midpoint

Evelo Biosciences logo

Evelo Biosciences, an early-stage biotech developing microbial gut therapies for inflammatory diseases, raised $85 million by offering 5.3 million shares at $16, within the range of $15 to $17. Evelo Biosciences plans to list on the Nasdaq under the symbol...read more

Pushing preclinical: Wave of early-stage biotech IPOs tests investor risk appetite

Evelo Biosciences logo

Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018,...read more

US IPO Week Ahead: AXA Equitable targets $3.5 billion in largest IPO since 2014

EQH

Headlined by AXA Equitable’s $3.5 billion offering, five companies are scheduled to raise nearly $4 billion in the week ahead. Other deals include Chinese e-sports platform Huya, early-stage biotechs Evelo Biosciences and Abpro, and Louisiana-based Origin...read more